SOW
BCRX icon

State of Wyoming’s BioCryst Pharmaceuticals BCRX Stock Holding History

State of Wyoming’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$583K Sell
58,264
-45,598
-44% -$412K 0.06% 314
2026
Q1 		$989K Buy
103,862
+51,969
+100% +$404K 0.12% 91
2025
Q4 		$405K Buy
51,893
+14,810
+40% +$107K 0.04% 509
2025
Q3 		$281K Buy
37,083
+10,433
+39% +$86.9K 0.03% 727
2025
Q2 		$239K Sell
26,650
-2,732
-9% -$25.4K 0.03% 792
2025
Q1 		$220K Sell
29,382
-12,921
-31% -$104K 0.03% 746
2024
Q4 		$318K Sell
42,303
-10,214
-19% -$77.5K 0.04% 518
2024
Q3 		$399K Buy
52,517
+45,682
+668% +$347K 0.06% 281
2024
Q2 		$42.2K Sell
6,835
-4,083
-37% -$22.5K 0.01% 1377
2024
Q1 		$55.5K Buy
10,918
+7,079
+184% +$39.8K 0.01% 1262
2023
Q4 		$23K Buy
3,839
+481
+14% +$2.79K ﹤0.01% 1536
2023
Q3 		$23.8K Buy
3,358
+1,128
+51% +$8.11K 0.01% 1486
2023
Q2 		$15.7K Buy
2,230
+988
+80% +$7.93K ﹤0.01% 1442
2023
Q1 		$10.4K Sell
1,242
-1,789
-59% -$17.2K ﹤0.01% 1484
2022
Q4 		$34.8K Buy
+3,031
New +$37.8K 0.01% 1171
2022
Q3 		– Sell
-1,082
Closed -$11K – 1551
2022
Q2 		$11K Buy
1,082
+261
+32% +$2.69K 0.01% 1621
2022
Q1 		$13K Buy
821
+138
+20% +$2.21K 0.01% 1560
2021
Q4 		$9K Sell
683
-37
-5% -$490 ﹤0.01% 1680
2021
Q3 		$10K Sell
720
-346
-32% -$5.46K 0.01% 1024
2021
Q2 		$17K Buy
1,066
+565
+113% +$7.68K 0.01% 949
2021
Q1 		$5K Buy
+501
New +$5.17K 0.01% 439

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State of Wyoming's BCRX Position: Q2 2026 in Review

State of Wyoming reduced its BioCryst Pharmaceuticals (BCRX) stake by 44% in Q2 2026, selling an estimated $412K and leaving 58,264 shares worth $583K. The position accounts for 0.06% of the portfolio, ranked #314.

State of Wyoming first reported a position in BCRX in Q1 2021 and has held it in 21 quarters since. The position peaked at $989K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • State of Wyoming held 58,264 shares of BioCryst Pharmaceuticals worth $583K as of Q2 2026.
  • State of Wyoming sold 45,598 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $412K.
  • BioCryst Pharmaceuticals made up 0.06% of State of Wyoming's portfolio in Q2 2026, its #314 holding.
  • State of Wyoming first reported a position in BioCryst Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • State of Wyoming's BioCryst Pharmaceuticals position peaked at $989K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.